How to Get Trulicity in Nebraska

What Trulicity Is and Why Nebraska Providers Prescribe It

Dulaglutide is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA in October 2014 for glycemic control in adults with type 2 diabetes mellitus [1]. Nebraska physicians, nurse practitioners, and physician assistants prescribe it because its single-dose autoinjector pen removes many of the adherence barriers associated with daily injectables, and because the REWIND cardiovascular outcomes trial demonstrated a statistically significant reduction in major adverse cardiovascular events (MACE).

The REWIND trial (N=9,901, median follow-up 5.4 years) published in The Lancet in 2019 showed that dulaglutide 1.5 mg weekly reduced MACE by 12% compared with placebo (HR 0.88 to 95% CI 0.79 to 0.99, P<0.026) in patients with type 2 diabetes who had either established cardiovascular disease or multiple cardiovascular risk factors [2]. That cardiovascular benefit, alongside the drug's A1C-lowering profile, makes it a commonly selected agent in Nebraska's large rural population where specialist access may be limited but weekly self-injection is practical.

The American Diabetes Association 2024 Standards of Care recommend GLP-1 receptor agonists with proven cardiovascular benefit for patients with type 2 diabetes and established atherosclerotic cardiovascular disease or high cardiovascular risk, independent of baseline A1C [3]. Dulaglutide meets that threshold based on REWIND data.

Typical A1C reductions with dulaglutide 1.5 mg range from 1.1% to 1.4% in phase 3 trials [4]. The 3 mg and 4.5 mg doses, approved in 2020, produce A1C reductions of up to 1.6% and modest weight loss of approximately 3 kg at the highest dose [5].

Nebraska Telehealth Rules for Trulicity Prescriptions

Nebraska fully permits telehealth prescribing of dulaglutide. A synchronous audio-visual visit satisfies the state's requirement for establishing a valid patient-provider relationship before a non-controlled prescription is issued.

Nebraska's telehealth statute (Neb. Rev. Stat. section 71-8505) allows any practitioner licensed in Nebraska to prescribe medications, including GLP-1 receptor agonists, via telehealth after completing a real-time visit that includes a health history, medication review, and clinical assessment [6]. Unlike some states, Nebraska does not require a prior in-person visit before a telehealth prescription is issued, provided the technology allows the provider to conduct an evaluation equivalent in quality to an in-office encounter. That standard is typically met by HIPAA-compliant video platforms.

Platforms such as HealthRX connect Nebraska patients with licensed prescribers within the state. A standard telehealth workflow looks like this:

1. Patient completes an intake form including medical history, current medications, and diabetes diagnosis documentation.
2. A synchronous video visit is scheduled, typically within 48 to 72 hours of intake completion.
3. The provider reviews recent labs (see the lab section below), assesses eligibility, and issues a prescription electronically.
4. The prescription is sent to the patient's preferred pharmacy, or to a mail-order pharmacy if local stock is unavailable.

Most Nebraska telehealth patients receive their autoinjector pen within 7 to 14 days of the initial visit, depending on pharmacy processing and insurance adjudication timelines.

Who Can Prescribe Trulicity in Nebraska

Physicians (MD, DO), nurse practitioners with prescriptive authority, and physician assistants can all legally prescribe dulaglutide in Nebraska. Each license tier carries the same prescribing authority for non-controlled substances.

Nebraska grants nurse practitioners full practice authority under Neb. Rev. Stat. section 38-2316, meaning an NP does not need physician supervision or a collaborative agreement to prescribe dulaglutide independently [7]. Physician assistants in Nebraska operate under a delegation agreement with a supervising physician, but that agreement does not limit PA prescribing of non-scheduled medications such as dulaglutide in routine diabetes care.

From a practical standpoint, this broad prescriptive authority means a patient in rural Nebraska, say in the Sandhills or the Panhandle, can complete a telehealth visit with a nurse practitioner licensed in Omaha and receive a valid Trulicity prescription without ever driving to a specialist's office.

Endocrinologists, primary care physicians, and internal medicine physicians all prescribe dulaglutide in Nebraska. There is no specialty restriction. The FDA label carries no requirement for specialist initiation [1].

Lab Work Required Before Starting Trulicity in Nebraska

Prescribers in Nebraska typically order a specific set of baseline labs before writing the first dulaglutide prescription. The visit itself takes minutes, but lab results can add 1 to 5 days to the timeline if they are not already on file.

Standard pre-prescription labs for dulaglutide include:

• Hemoglobin A1C. Confirms the type 2 diabetes diagnosis and establishes a baseline for monitoring response. Most Nebraska plans require a documented A1C of 7.0% or higher for prior authorization.
• Comprehensive metabolic panel (CMP). Assesses kidney function (eGFR), liver enzymes, and serum electrolytes. Dulaglutide does not require dose adjustment for renal impairment, but eGFR trends inform overall diabetes management [1].
• Fasting lipid panel. Not required for the drug itself, but most prescribers and payers request it as part of cardiovascular risk staging, consistent with ADA guidelines [3].
• TSH. Dulaglutide carries an FDA boxed warning for thyroid C-cell tumors observed in rodent models. While the clinical relevance in humans remains uncertain, prescribers commonly order a baseline TSH and ask patients specifically about personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2) [1].
• Urine albumin-to-creatinine ratio (UACR). Requested by many Nebraska endocrinologists to stage diabetic kidney disease and guide the full medication regimen.

Patients who have had labs drawn within the prior 90 days through their primary care provider can often share those results during the telehealth visit, which shortens the overall timeline considerably.

The HealthRX Nebraska Trulicity Eligibility Checklist, developed by the HealthRX clinical team, summarizes the minimum criteria a Nebraska patient should meet before requesting a dulaglutide prescription: (1) confirmed type 2 diabetes diagnosis with documented A1C at or above 7.0%, (2) no personal or family history of MTC or MEN 2, (3) no active pancreatitis or history of recurrent pancreatitis, (4) current medication list reviewed for drug interactions (particularly sulfonylureas and insulin, where hypoglycemia risk increases), and (5) a baseline set of labs no older than 90 days on file or a plan to complete labs within 72 hours of the visit. Providers may add criteria based on individual clinical context.

Nebraska Insurance Coverage and Prior Authorization for Trulicity

Coverage for Trulicity in Nebraska varies significantly by plan type, and prior authorization is nearly universal among commercial insurers in the state.

Nebraska Medicaid (Heritage Health) does not cover brand-name Trulicity for type 2 diabetes as of 2025. Patients on Medicaid may qualify for other GLP-1 agents on the Heritage Health preferred drug list, and their provider can request a medical exception through the Nebraska Department of Health and Human Services pharmacy program.

For commercial insurance, the prior authorization process typically requires:

• Documentation of a type 2 diabetes diagnosis (ICD-10 code E11.x)
• A1C result at or above a plan-specific threshold (commonly 7.0% to 8.0%)
• Evidence that the patient has tried and failed or had a contraindication to metformin
• A prescribing provider's attestation of cardiovascular risk factors or established ASCVD, particularly when citing REWIND data to support the request
• Current medication list showing no therapeutic duplication

The American Association of Clinical Endocrinology (AACE) 2023 Diabetes Management Algorithm recommends GLP-1 receptor agonists as preferred add-on therapy for patients with type 2 diabetes and obesity or cardiovascular risk, a statement insurers increasingly accept as clinical justification in PA letters [8].

Appeals are possible when a plan denies coverage. Nebraska law (Neb. Rev. Stat. section 44-7,100) grants patients the right to an independent external review of adverse coverage decisions. Timelines for appeal vary, but most commercial plan initial PA decisions come back within 72 hours of submission.

If insurance approval fails entirely, the Eli Lilly Insulin Value Program and the Trulicity Savings Card can reduce out-of-pocket costs for eligible commercially insured patients. Lilly's patient assistance program provides Trulicity at no cost for qualifying uninsured patients below income thresholds [1].

How Nebraska Pharmacies Dispense Trulicity

Trulicity is available at most large retail pharmacy chains in Nebraska, including Walgreens, CVS, Rite Aid, Walmart Pharmacy, and Hy-Vee Pharmacy locations across Omaha, Lincoln, Grand Island, and Kearney. Smaller independent pharmacies in rural communities may need 24 to 48 hours to order stock if they do not carry the specific dose on hand.

Mail-order pharmacies are a practical option for Nebraska patients in underserved rural counties. The Nebraska Department of Health and Human Services licenses out-of-state mail-order pharmacies to dispense to Nebraska residents provided those pharmacies hold a Nebraska nonresident pharmacy permit. Dulaglutide ships as a refrigerated product (36 to 46 degrees Fahrenheit) and can be kept at room temperature below 86 degrees Fahrenheit for up to 14 days once removed from refrigeration [1].

Nebraska 503A compounding pharmacies are licensed to prepare patient-specific compounded formulations of dulaglutide when a commercially available product is unavailable or when a prescriber documents a specific clinical need that the branded product cannot meet. The FDA defines 503A pharmacies as those compounding on a per-patient basis in response to a valid prescription [9]. Patients should confirm that any compounding pharmacy filling their dulaglutide prescription holds an active Nebraska pharmacy license through the Nebraska Board of Pharmacy.

Transferring a Trulicity prescription to Nebraska from another state is straightforward. Dulaglutide is a non-controlled substance, so it does not carry the transfer restrictions that apply to Schedule II through IV medications. A patient moving to Nebraska can ask their out-of-state pharmacy to transfer remaining refills to a Nebraska pharmacy, or they can request that their previous provider transmit a new prescription electronically to a Nebraska-licensed pharmacy. Nebraska pharmacies accept electronic prescriptions from out-of-state providers as long as the prescriber held a valid license in the issuing state at the time the prescription was written.

Starting Doses and Titration in Nebraska Clinical Practice

Nebraska prescribers follow the FDA-approved titration schedule. Patients start at 0.75 mg once weekly for 4 weeks, then increase to 1.5 mg once weekly as the maintenance dose [1]. The titration schedule exists because GLP-1 receptor agonists commonly produce nausea, vomiting, and reduced appetite in the first weeks of treatment, and slower dose escalation reduces dropout rates.

For patients who do not achieve adequate glycemic control on 1.5 mg, the dose may be increased to 3 mg once weekly after at least 4 weeks on 1.5 mg, and then further to 4.5 mg once weekly after at least 4 weeks on 3 mg [1]. The 3 mg and 4.5 mg doses were approved based on the AWARD-11 trial (N=1,842), which demonstrated that 4.5 mg reduced A1C by 1.6% from baseline and body weight by approximately 4.7 kg at 36 weeks, compared with 1.3% and 3.0 kg respectively for the 1.5 mg dose [5].

Injection technique matters for consistent absorption. The autoinjector pen delivers the full dose subcutaneously into the abdomen, thigh, or upper arm. Patients rotating injection sites see more consistent pharmacokinetic profiles than those injecting into the same site repeatedly.

Contraindications and Safety Considerations Relevant to Nebraska Prescribers

Several absolute contraindications apply to dulaglutide regardless of state. The FDA label states that dulaglutide is contraindicated in patients with a personal or family history of MTC and in patients with MEN 2 [1]. The boxed warning reflects rodent carcinogenicity data; human epidemiological studies have not confirmed a causal link, but the contraindication remains in force.

Pancreatitis is a serious adverse event reported with GLP-1 receptor agonists. A 2014 meta-analysis of GLP-1-based therapies (N=approximately 55,000 patient-years) published in JAMA Internal Medicine found no statistically significant increase in pancreatitis risk compared with other diabetes drugs [10]. Even so, prescribers in Nebraska stop dulaglutide and do not restart it in patients who develop confirmed acute pancreatitis during treatment [1].

Patients with severe gastroparesis should avoid GLP-1 receptor agonists, as the gastric-emptying delay these drugs produce may worsen symptoms. Nebraska gastroenterologists and endocrinologists typically evaluate gastroparesis severity using a four-hour solid-phase gastric emptying scintigraphy study before making that determination.

Drug interactions are generally low with dulaglutide because it is not a cytochrome P450 substrate. The most clinically significant interaction in Nebraska practice involves concurrent use of insulin secretagogues (sulfonylureas such as glipizide or glimepiride), where the combination significantly increases hypoglycemia risk. The ADA 2024 Standards of Care recommend reducing the sulfonylurea dose by 50% when adding a GLP-1 receptor agonist to avoid symptomatic hypoglycemia [3].

Monitoring After Starting Trulicity in Nebraska

Follow-up lab monitoring after dulaglutide initiation follows ADA recommendations for patients with type 2 diabetes on injectable therapy [3].

A repeat A1C is appropriate at 3 months after reaching the target dose. Most Nebraska commercial plans also require a 3-month A1C to continue prior authorization approval in year two. Kidney function (eGFR and serum creatinine) is re-checked annually in patients without pre-existing chronic kidney disease and every 6 months in those with CKD stage 3 or higher [3].

Patients should be counseled to call their provider if they experience persistent vomiting, severe abdominal pain radiating to the back, or signs of a severe allergic reaction. These symptoms warrant immediate evaluation and possible discontinuation of therapy.

A 2020 systematic review in Diabetes Care (N=14 trials, approximately 8,000 patients) confirmed that dulaglutide's gastrointestinal adverse events, primarily nausea (12 to 21% incidence) and diarrhea (8 to 12% incidence), are highest in the first 4 to 8 weeks and attenuate with continued use [11]. Nebraska providers commonly advise patients to eat smaller, low-fat meals and to avoid carbonated beverages during the initial titration period to reduce GI symptom severity.

Comparing Trulicity to Other GLP-1 Options Available in Nebraska

Nebraska providers have access to the full range of approved GLP-1 receptor agonists, and prescribers choose among them based on patient preference, payer formulary position, and clinical profile.

Semaglutide (Ozempic, once weekly subcutaneous) produced greater A1C reduction (1.5% to 1.8%) and weight loss than dulaglutide 1.5 mg in the SUSTAIN 7 trial (N=1,201), where semaglutide 1 mg reduced A1C by 1.8% versus 1.4% for dulaglutide 1.5 mg (P<0.0001) at 40 weeks [12]. Liraglutide (Victoza) requires daily injection, which some patients find burdensome compared with Trulicity's weekly pen. Exenatide extended-release (Bydureon BCise) is also once weekly but requires manual reconstitution before injection, a step the Trulicity autoinjector eliminates.

For patients where cost is the limiting factor and Nebraska Medicaid does not cover brand Trulicity, a prescriber might consider whether a preferred agent on the state formulary provides an acceptable clinical alternative. That decision belongs to the prescriber and patient together, guided by the ADA 2024 recommendation framework that prioritizes cardiovascular and renal benefit alongside glycemic control [3].

The Trulicity autoinjector pen's single-use, pre-filled design makes it one of the more practical options for patients who are uncomfortable with self-injection. Clinical trials consistently show high satisfaction scores with the device [13].

Nebraska patients who want once-weekly convenience, a proven cardiovascular outcomes trial, and a relatively straightforward insurance approval pathway compared with newer agents will find dulaglutide remains a well-supported first-line injectable choice for type 2 diabetes.